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Ras/MAPKAnnexin A6 (AnxA6) belongs to a conserved family of Ca2+-dependent membrane-binding proteins. Like other
annexins, the function of AnxA6 is linked to its ability to bind phospholipids in cellular membranes in a dynamic
and reversible fashion, in particular during the regulation of endocytic and exocytic pathways. High amounts of
AnxA6 sequester cholesterol in late endosomes, thereby lowering the levels of cholesterol in the Golgi and the
plasma membrane. These AnxA6-dependent redistributions of cellular cholesterol pools give rise to reduced
cytoplasmic phospholipase A2 (cPLA2) activity, retention of caveolin in the Golgi apparatus and a reduced
number of caveolae at the cell surface. In addition to regulating cholesterol and caveolin distribution, AnxA6 acts
as a scaffold/targeting protein for several signaling proteins, the best characterized being the Ca2+-dependent
membrane targeting of p120GAP to downregulate Ras activity. AnxA6 also stimulates the Ca2+-inducible
involvement of PKC in the regulation of HRas and possibly EGFR signal transduction pathways. The ability of
AnxA6 to recruit regulators of the EGFR/Ras pathway is likely potentiated by AnxA6-induced actin remodeling.
Accordingly, AnxA6may function as an organizer ofmembrane domains (i) tomodulate intracellular cholesterol
homeostasis, (ii) to create a scaffold for the formation of multifactorial signaling complexes, and (iii) to regulate
transient membrane–actin interactions during endocytic and exocytic transport. This article is part of a Special
Issue entitled: 11th European Symposium on Calcium.group A; BCC, breast cancer
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Annexins are a dynamic and multifunctional family of structurally
related calcium and membrane-binding proteins that have been
identiﬁed in a large variety of species ranging from protists to higher
vertebrates and are classiﬁed into ﬁve groups (A–E), with the 12
human and vertebrate annexins representing group A [1,2]. All
annexins are composed of two domains: a conserved core that is
responsible for Ca2+- and phospholipid-binding, and a variable N-
terminal tail. Although synthesized as cytosolic proteins, annexins are
predominantly associated with different intracellular membranes aswell as the plasma membrane primarily due to their ability to bind
negatively charged phospholipids in a Ca2+-dependent manner. This
provides a connection between Ca2+ signaling and membrane
functions and enables annexins to participate in the organization of
membrane domains or signaling platforms and the formation of
complex protein networks. Their dynamic nature, together with the
high amounts and multiple locations of annexins found in most cells
and tissues, probably accounts for annexins being implicated in awide
variety of otherwise unrelated events ranging from membrane
dynamics to cell differentiation and migration.
Crystallographic studies and experimental approaches utilizing
model membranes provided the biophysical framework to under-
stand the topology, details of the membrane-binding side, interac-
tions with other proteins (exempliﬁed by the S100 family), ligand
binding sites and afﬁnities to various phospholipids (and cholesterol)
[3]. Furthermore, in vivo studies using annexin knockout-mice and
knockdown approaches in cell culture have further identiﬁed
processes that depend on annexins, including certain membrane-
trafﬁcking steps, aspects of Ca2+ signaling, but also extracellular
events.
In this review, we will focus on the largest member of the annexin
family, annexin A6 (AnxA6). AnxA6 is the only annexin that contains
two annexin cores within a single physical entity, which probably
arose from the duplication and fusion of the genes encoding for
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associationwith artiﬁcial membranes show that the two coremodules
can probably orient themselves in a ﬂexible manner relative to one
another. This allows the molecule to bind with its core domains
attached to either one membrane or to two separate membranes [4–
7] (Fig. 1). AnxA6 binds to phosphatidylserine (PS), phosphatidyli-
nositol, phosphatidic acid [2], and earlier reports also identiﬁed
afﬁnity towards phosphatidylethanolamine and arachidonic acid [8].
Besides the Ca2+-dependent targeting of AnxA6 to membranes, acidic
pH and cholesterol also regulate the targeting and trafﬁcking events
for this annexin [9–14].
In addition to its membrane binding properties, AnxA6 interacts
with members of the actin cytoskeleton and multiple signaling
proteins. In this review we will make an attempt to characterize the
features that enable AnxA6 to regulate membrane trafﬁcking and
signal transduction: the ability of AnxA6 (1) to regulate caveolin-1
transport, cellular cholesterol distribution and cPLA2 activity, but also
(2) to organize the cytoskeleton and (3) the formation of multifac-
torial, PKC and HRas containing signaling complexes.
2. AnxA6 and cholesterol homeostasis
Cholesterol is an essential structural constituent of cellular
membranes in eukaryotes. Mammalian cells synthesize their own
cholesterol but also receive exogenous cholesterol through lipopro-
tein uptake. The intracellular routes for the transport of cholesterol—
vesicular and non-vesicular—between membrane compartments are
complex and their regulation is still not fully understood [15,16]. One
important consequence of these various transport routes is that
cholesterol is not uniformly distributed in biological membranes, but
enriched in speciﬁc membrane domains. Certain proteins are found in
these cholesterol-rich domains (membrane rafts), and thus inﬂuence
the functioning of the plasma membrane.
As outlined above, annexins interact with negatively charged
membrane phospholipids in a Ca2+-dependent manner and up to
date, have generally been considered not to bind cholesterol.
However, the mutational analysis of the annexin core and N-terminal
tail showed that cholesterol can increase the Ca2+-dependent
membrane binding and aggregation of AnxA2. Similarly, AnxA5 and
AnxA6, two annexins with unrelated N-terminal tails but homologous
core domains, also showed a Ca2+-dependent binding to membranesFig. 1. Annexin A6 protein structure. (A) The eight repeats of AnxA6 are shown, and the locali
[177]. The position of phosphorylation sites at S13, Y30, T356 and the larger splice variant
[178], where visible Ca2+ (red) and putative phosphorylation sites (yellow) are highlighted
linker region of human AnxA6. The putative phosphorylation sites within the N-terminus (S
linker at Trp343 (W343) [11] are indicated.that was cholesterol-sensitive [17,18]. Smart et al. [19,20] further
challenged the concept of annexins as non-cholesterol binding
proteins and isolated AnxA2 from a cytosolic complex together with
cholesterol and caveolin. Further pointing at the possibility of AnxA2
to interact with cholesterol, AnxA2 translocates to cholesterol-rich
late endosomes in ﬁbroblasts from patients with the cholesterol-
storage disorder Niemann-Pick C [21]. From these studies it was
speculated that cholesterol potentially affects the membrane binding
afﬁnity of other annexins as well, and eventually, their intracellular
localization. Hence, annexins could indeed contribute to cholesterol-
related events in biological membranes through the re-arrangement
of microdomains [17,22].
In support of this hypothesis, we identiﬁed two different pools of
AnxA6 in Chinese Hamster Ovary (CHO) cells. While the majority
(70–80%) of AnxA6 bound to membranes in a Ca2+-dependent
manner, the remaining AnxA6 proteins associated with endosomal
membranes even in the absence of Ca2+. This pool of Ca2+-
independent AnxA6 proteins is strongly inﬂuenced by the amount
and distribution of cholesterol. Cholesterol depletion using methyl-
β-cyclodextrin reduced the membrane binding of Ca2+-independent
AnxA6 proteins to early and late endosomes. Conversely, cholesterol-
loading of late endosomes, using low density lipoproteins (LDL) or
the amphipatic steroid U18666A, stimulated the binding of AnxA6 to
late endosomal membranes [13,14]. Since this translocation of AnxA6
was also observed in drug-induced, cholesterol-rich late endosomes
of NRK ﬁbroblasts, we proposed that cholesterol is a general and
additional modulator of AnxA6-membrane binding and intracellular
distribution. In line with these data, recent studies suggest Ca2+-
independent and cholesterol-, but not cholesteryl acetate, dependent
membrane-binding properties of recombinant AnxA6, implicating
the hydroxyl group of cholesterol in AnxA6-membrane interaction
[11].
Moreover, it is now well-documented that acidic pH induces
conformational changes in AnxA6 leading to increased hydrophobic-
ity, membrane binding afﬁnity [23–25] and high preference for
monolayers containing cholesterol. In model membranes at acidic pH,
the tryptophan 343 residue (Trp343) within the linker region of
AnxA6 seems to be important for the interaction of AnxA6 with
cholesterol in a Ca2+-independent manner [11]. Fig. 2 depicts, in a
simpliﬁed scheme, the steps within intracellular cholesterol transport
pathways and the locations of the various annexins possibly involved.zation of the six potential calcium-binding sites in repeats 1, 2, 4, 5, 6 and 8 are indicated
(Pos. 524–529) [173] are highlighted. (B) Atomic space-ﬁlling model of bovine AnxA6
. (C) Schematic representation of the amino acid sequences in the N-terminal and the
13, Y30) and linker (T356) as well as the potential cholesterol-binding site (chol) in the
Fig. 2. Potential involvement of annexins in cholesterol transport. Scheme showing the localization and regulatory function of annexins in major cholesterol trafﬁcking pathways
[15]: Cholesterol synthesized in the endoplasmic reticulum (ER) is predominantly transported directly (4) or to a minor extend indirectly via the Golgi (1) and trans-Golgi network
(TGN) to the plasma membrane (PM), where it is distributed either to raft (2) (solid gray) or non-raft (3) microdomains. Cholesterol can be internalized from the plasmamembrane
by endocytosis via clathrin-coated vesicles (5) or other pathways, including caveolae (6). From early/sorting endosomes (EE/SE), cholesterol is recycled to the surface via recycling
endosomes (RE) (7) or transported back to the ER (8). Exogenous cholesterol is internalized via LDL receptor-mediated endocytosis through clathrin-coated pits (5), transported to
EE/SE, then to late endosomes (LE) (9) and ﬁnally lysosomes (Lys). Exchange of cholesterol between all endo- (EE, SE, LE) and exocytic (TGN) compartments is known to occur (10).
In LE/Lys, LDL-derived cholesteryl esters are hydrolyzed prior to release to the PM, endosomes, ER and Golgi. In the ER, cholesterol may become re-esterifed and deposited in
cytosolic lipid droplets (LD) (11) fromwhere cholesterol can bemobilized upon ester hydrolysis. Caveolae have been implicated in the uptake of cholesterol esters fromHDL. Finally,
cholesterol export from cells, cholesterol efﬂux (12), predominantly occurs at the PM, but can involve cholesterol delivery from EE/SE/RE and in particular LE. Encircled in white are
those steps of cholesterol transport where annexins (A1, A2, A4, A5 and A6) might participate. As outlined in the text, AnxA6 is involved in LDL endocytosis and cholesterol transport
to LE. AnxA6 also regulates cholesterol export from LE and one report identiﬁed AnxA6 and AnxA2 in LD [179]. Several other annexins have been found associated with membrane
rafts. A more detailed description on the link of these annexins (AnxA1, AnxA2, AnxA4, AnxA5) with cholesterol can be found in [2,17–21,42,179–185]. PS, phosphatidylserine; PC,
phosphatidylcoline; cer, ceramide.
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terol in late endocytic (pre-lysosomal) compartments have important
consequences for cellular cholesterol homeostasis [26]. Late endoso-
mal/prelysosomal cholesterol is exported to various locations in the
cell, including the Golgi apparatus and the cell surface. In normal cells
at steady state, very little cholesterol is detected in late endosomes
and lysosomes as cholesterol derived from the hydrolysis of
internalized LDL is rapidly transported out of late endosomes [27–
29]. However, cells carrying Niemann-Pick type C (NPC) mutations or
treatedwith U18666A (or progesterone) accumulate large amounts of
cholesterol in late endosomes and allow studies to address the
consequences of blocking cholesterol export from this compartment
to other cellular sites.
The sequestration of cholesterol in late endosomes of AnxA6
expressing cells is not only representative of an NPC-like phenotype,
but also associated with reduced cholesterol levels in other cellular
compartments, in particular the Golgi and the plasma membrane.
Furthermore, increased late endosomal cholesterol is accompanied by
a rearrangement of the intracellular localization/distribution of
AnxA6, leading to the translocation of a signiﬁcant amount of
AnxA6 proteins to this compartment [13,14]. Reduced cholesterol
levels in the Golgi and at the cell surface are probably responsible for
the retention of caveolin-1 in the Golgi complex and the reduced
number of caveolae observed at the cell surface. Given that AnxA6
expression correlates with the number of caveolae in various cell
types [26], we hypothesize that AnxA6 expression levels could be a
marker indicative of the potential abundance of caveolae in quite a lot
of different cells and tissues.
Interestingly, only studies with a dominant negative mutant of
caveolin-3 (cavDGV) and mutants of the NPC1 protein have shown a
phenotype similar to AnxA6-expressing cells and further suggest a linkbetween late endosomal cholesterol pools and caveolin localization. As
shown for AnxA6, cavDGV causes an intracellular accumulation of
cholesterol in late endosomes, a decrease in cholesterol synthesis and
cell surface cholesterol, and a reduction in cholesterol efﬂux [30].
Furthermore cavDGV-transfected cells also exhibit a signiﬁcant reduc-
tion in the number of caveolae. These changes in cavDGV expressing
cells are associated with dramatic alterations in cholesterol-depen-
dent signaling events, such as the inhibition of HRas-induced
activation of Raf-1, and subsequent reduction of growth factor-
dependent cell growth [31]. Similarly, we showed that AnxA6 inhibits
epidermal growth factor (EGF) and platelet-derived growth factor
(PDGF), but also High-Density Lipoprotein (HDL)-induced activation
of HRas and Raf-1, which has been proposed to require the binding
of HDL to SR-BI in caveolae [32–35]. In addition, restoration of
AnxA6 expression reduces cell proliferation in AnxA6-deﬁcient
A431 cells as well as breast cancer cell lines with low AnxA6 levels
[36–38]. Thus, the mechanisms underlying the effects of AnxA6 on
cholesterol and caveolin-1 transport could provide explanations for
the role of caveolae in the regulation of signal transduction and cell
growth.
As mentioned above, AnxA6 and cavDGV-expressing cells show a
phenotype that partially resembles alterations in cholesterol trans-
port observed in cells carrying amutation in the NPC1 protein. NPC1 is
involved in cholesterol homeostasis and has been proposed to
regulate caveolin expression and localization [39,40]. Despite the
co-immunoprecipitation of AnxA6 and NPC1 [26], AnxA6 has been
shown to localize to endocytic compartments in NPC1-deﬁcient cells
[10,41], indicating that the role of AnxA6 in late endosomes might not
require NPC1 function. Further pointing at differences in their modes
of action, caveolin and NPC1/2 are cholesterol-binding proteins and/
or more directly involved in cholesterol transport.
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related to cholesterol homeostasis for AnxA6 that might not entail
direct interaction of AnxA6 with cholesterol nor NPC1 or caveolin:
i) the formation of cholesterol-rich membrane domains at the plasma
membrane [2,42,43], thereby controlling membrane cholesterol,
caveolae formation and possibly actin dynamics (see below), and
ii) the regulation of NPC1-containing membrane domains in the
late endocytic compartment, modulating intracellular cholesterol
distribution.
At the plasma membrane, AnxA6 could be associated with the
formation of PS-rich domains, thus affecting the activity of proteins
residing in neighboring cholesterol-rich domains that control choles-
terol transport. On the other hand and despite AnxA6 translocating to
late endosomes from NPC1-deﬁcient cells (see above), the co-
localization and co-immunoprecipitation of AnxA6 and NPC1 in late
endosomes could indicate that AnxA6 may directly downregulate
NPC1 activity. This could ultimately control the amount of caveolin-1
at the plasma membrane. In support of both models, we showed that
the accumulation of Golgi-associated caveolin-1 in a CHO cell line
with high amounts of AnxA6 (CHOanx6) could be overcome upon
addition of exogenous cholesterol or overexpression of NPC1 [26].
Recently, we also addressed whether the accumulation of cholesterol
in the late endocytic compartment is associated with perturbed
sphingolipid metabolism, transport or degradation. In fact, prelimi-
nary data derived from glycosphingolipid staining using Bodipy-
LacCer and HPLC analysis of isolated late endosomal detergent
resistant membranes (DRMs) indicate that CHOanx6 cells accumulate
glycosphingolipids in the late endocytic compartment (Rentero,
Grewal and Enrich, unpublished). These ﬁndings, together with less
cholesterol and caveolae at the cell surface of CHOanx6 cells might be
linked to observations in cells from caveolin-1 ko-mice, which seem to
compensate loss of caveolin through higher levels of sphingomyelin
(SM) and saturated phospholipids resulting in the formation of non-
caveolae raft domains [44].
In summary, we conclude that AnxA6 produces alterations in
cholesterol export from late endosomes, and possibly in cholesterol
synthesis [26], thereby contributing to an imbalance and altered
distribution of cholesterol in other compartments like the Golgi
apparatus and the cell surface.
2.1. cPLA2 and AnxA6: Implications for membrane trafﬁcking
As discussed in the previous section, cholesterol export from late
endosomes partially determines the availability of cellular cholesterol
in other compartments. In the following we will summarize how this
can be directly related to the vesiculation and tubulation of Golgi
membranes and subsequently, membrane trafﬁcking and cargo
export from the Golgi. The regulation of Golgi export is very complex,
and in this section we will focus on cytoplasmic phospholipase A2
(cPLA2) as an integral part of this molecular machinery regulating the
secretory pathway [45].
The association of annexins with phospholipase A2 activity has a
long history, and is closely linked with the discovery of annexin A1
and A2. The superfamily of PLA2 enzymes consists of 15 groups
comprising secretory and cytosolic enzymes, with the latter divided
into Ca2+-sensitive and -insensitive isoforms. Whereas the inhibition
of secreted members of the PLA2 family by annexins is well
documented andmight be explained by annexins and PLA2 competing
for the same binding site at the membrane surface, little is still known
about the potential of annexins to modulate cytosolic members of the
PLA2 family [3]. In respect to the Golgi apparatus, only the cPLA2α
isoform among the Ca2+-sensitive members of cPLA2 is normally
cytosolic and associates with the Golgi complex upon moderate
increases in Ca2+. cPLA2α exhibits a preference for the sn-2
arachidonyl group in phospholipids to control the levels of free
arachidonic acid (AA) in cells [46].Several studies have demonstrated that cPLA2 activity in the Golgi
is cholesterol-sensitive, mainly due to its translocation to Golgi
membranes in response to increased cellular cholesterol levels [47–
49]. This facilitates the generation of lysophospholipids and AA, to
drive the formation of positive membrane curvature, a requirement
for Golgi vesiculation. We demonstrated that reduced Golgi-choles-
terol levels in AnxA6 expressing CHO cells (CHOanx6), correlated
with cPLA2α displacement from Golgi membranes, which probably
explains the loss of cPLA2 activity, as judged by reduced AA secretion
[50]. Control experiments using drug-induced NPC-like cells con-
ﬁrmed that the retention of cholesterol in late endosomes of CHOanx6
cells [26] is likely to be the underlying cause of the impaired supply of
cholesterol to the Golgi, thereby interfering with cholesterol-sensitive
cPLA2 translocation to the Golgi and vesiculation. The alteration of
cPLA2 activity and translocation would ultimately not only reduce
Golgi vesiculation/tubulation, but also down-regulate the availability
of newly synthesized cholesterol acceptors, such as caveolin-1, for
vesicular or non-vesicular export of cholesterol from other compart-
ments, including late endosomes [51]. Accordingly, this regulatory
circuit involving cholesterol export from late endosomes enables
AnxA6 to be indirectly linked with the secretory pathway (Fig. 3).
Importantly, cholesterol and AA not only affect Golgi vesiculation,
but also modulate the localization/activity of SNARE [SNAP (soluble
NSF Attachment Protein) Receptor] and SM (Sec1p/Munc18) proteins,
which mediate vesicular targeting, docking and fusion that underlie
membrane trafﬁcking and exocytosis [52]. As such, AA can stimulate
Munc18-regulated SNARE complex formation [53] and membrane-
associated cPLA2 can upregulate AA levels at the membrane where
syntaxins (t-SNAREs) reside. This is followed by the induction of an
“open” conformation, required for the stimulation of SNARE interac-
tions [53,54].
As indicated below, the ability of AnxA6 to reduce AA levels might
interfere with SNARE complex formation through modulation of
syntaxins 4, 6 and SNAP23 localization and activity. For example,
Syntaxin-4, the non-neuronal syntaxin-1, requires AA to participate in
SNAREcomplex formation [55]. Addition of AA, or treatmentwith cPLA2,
is sufﬁcient to stimulate SNARE complex formation [53]. Syntaxin-4 and
SNAP23, two t-SNAREs family members located at the plasma
membrane, concentrate in cholesterol-rich clusters that partially co-
localize with caveolin-1 in endothelial basolateral plasmamembrane. It
has been suggested that this spatial organization may be required for
efﬁcient and rapid caveolar fusion with target membranes [56].
Most recently, the t-SNARE syntaxin-6 has been demonstrated
critical for cholesterol transport from late endosomes to the trans-
Golgi-network (TGN) [57], but also for the delivery of microdomain-
associated lipids and proteins to the cell surface, required for caveolae
endocytosis. Silencing of syntaxin-6 reduces the amount of different
proteins at the plasmamembrane, like caveolin-1, and correlates with
a reduced number of caveolae. This study implicated that this process
might require the direct interaction of syntaxin-6 with caveolin-1
[58]. Consistent with our model of AnxA6 inhibiting cholesterol-
sensitive cPLA2 activity, leading to reduced availability of AA in the
Golgi, work in progress in our laboratories indicates that AnxA6
negatively modulates the location of the t-SNAREs SNAP23 and
syntaxin-4 at the plasma membrane. In addition we also observed
partial translocation of syntaxin-6 from the TGN to endosomal
vesicles in AnxA6 expressing CHO cells (Reverter, Grewal and Enrich,
unpublished). Further pointing at annexins regulating the SNARE
machinery, a recent study provides strong evidence for a tight and
Ca2+-dependent coupling between S100A10/AnxA2 and VAMP2
(v-SNARE) in adrenergic cells; the formation of this complex
controlling regulated exocytosis [59].
There is a great deal of evidence that regulation of cPLA2 activity/
localization is far more complex and besides AnxA6 additional players
like the lipid environment, the actin cytoskeleton, and the direct
interaction of the C2 domain of cPLA2 with other proteins should also
Fig. 3. Role of AnxA6 in late endosomal cholesterol transport and caveolae formation. In the left panel the route of caveolin (cav1) from the ER to the cell surface in cells with low
AnxA6 levels is indicated (blue arrows). Cholesterol (chol) uptake, transport from late endosomes (LE) to the Golgi and efﬂux pathways are depicted with red arrows. Cytoplasmic
phospholipase A2α (cPLA2α) is located in the Golgi and generates arachidonic acid (AA), which is transported to different membrane compartments. In cells with high AnxA6 levels
(right panel), cholesterol accumulation in LE (see enlarged LE compartment) is accompanied by a translocation of AnxA6 to LE/multivesicular bodies (LE/MVB), where AnxA6
interferes with Niemann-Pick C1 (NPC1) protein to inhibit cholesterol export to the Golgi apparatus. Cholesterol depletion in the Golgi inhibits the recruitment of cPLA2 to the Golgi
(green arrow), with the concomitant reduction of AA production, followed by reduced and cholesterol- and cPLA2-dependent caveolin transport to the cell surface. Diminished AA
levels affect trafﬁcking pathways and interfere with SNARE complex formation. Decreased amounts of caveolin-1 and cholesterol at the plasma membrane reduce caveolae
formation (and signaling). Dashed blue, red and green arrows indicate diminution or inhibition of those transport pathways [26,50].
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C2 domain of cPLA2 in vitro, including annexins A1 and A5 [60,61],
vimentin [62], and PLIP (cPLA2-interacting protein) [63]. Interestingly,
similar to the annexins, calcium is also involved in the regulation of
cPLA2 membrane targeting, through the interaction of the cPLA2 C2
domain, with membrane phospholipids. As discussed in more detail
below, the Ca2+-inducible membrane association of annexins is
accompanied by annexin–actin interactions. Given that inhibition of
cPLA2α activity blocked both growth factor-induced membrane and
actin dynamics, this could indicate a role for annexins, including
AnxA6, for the translocation of active cPLA2 to sites of actin
remodeling at the membrane [64].
Finally, cPLA2 contains a consensus sequence (Pro-Leu-Ser505-Pro)
for phosphorylation by the mitogen-activated protein kinase (MAPK)
extracellular signal-regulated kinase 1/2 (ERK1/2). ERK efﬁciently
phosphorylates cPLA2 at Ser505, which increases its enzymatic activity
[65–67]. This phosphorylation seems to be important to enable
activated cPLA2 to translocate to membrane vesicles and selectively
release AA from the sn-2 position of membrane phospholipids [68].
Interestingly, enhanced AA production through upregulation of cPLA2
activity has recently been shown to inhibit nuclear liver X receptor
(LXR), thereby reducing ATP binding cassette transporter A1 (ABCA1)
expression and cholesterol efﬂux in macrophages [69]. Since AnxA6
strongly inhibits the activity of Erk1/2 kinases [70,71] (see also
Section 4), it is tempting to speculate that the dual activities of AnxA6
to (1) reduce MAPK signal output and (2) inhibit cholesterol delivery
to the Golgi, cooperate to regulate cPLA2 in various settings relevant to
human disease, such as reverse cholesterol transport to prevent
atherosclerosis, but also in the production of AA during inﬂammation
as well as for tumor suppressor/promoter activities of caveolin-1 in
cancer.
2.2. AnxA6 and membrane structure
Annexins contribute to the architecture, functioning and structural
organization of membranes most likely through their binding tonegatively charged phospholipids, but also through protein–protein
interactions with a variety of membrane-associated proteins. But how
can annexins contribute to, or promote changes in the architecture of
membranes?
Annexins A2 and A6 were shown to translocate to DRMs
(membrane rafts) in a Ca2+-dependent manner, in smooth muscle
plasmalemma [42] and synaptic plasma membrane of rat brain [43].
Similar results were obtained for AnxA6 in CHO cells (Grewal and
Enrich, unpublished). At steady-state, AnxA6 and AnxA2 seem to be
components of membrane rafts (caveolae) as well as non-rafts
domains (clathrin-coated pits) and involved in endocytosis. In
clathrin-coated pits both annexins are associated with the μ-subunits
of the clathrin adaptor complex AP2 in a Ca2+-dependent manner
[72]. In addition, annexins A2 and A6 have been identiﬁed in isolated
caveolae fractions from different cells and tissues [73–77] and a
complex of AnxA2 and caveolin appears to facilitate the transport of
esteriﬁed cholesterol from the plasma membrane to internal
membranes [19,20].
As outlined in Section 2, upregulation of AnxA6 levels indirectly
affects cell membrane architecture through retention of caveolin in
the Golgi and diminution of the number of caveolae at the cell surface
[26]. These ﬁndings are consistent with studies showing that defects
in the export of caveolin from the Golgi due to loss of Golgi exit
information, exposure of retention signals or conformational changes
can contribute to regulate the number of caveolae. Nevertheless, the
molecular mechanism(s) regulating the exit of caveolin from the
Golgi complex and the formation of caveolae at the cell surface is not
fully understood. Recently the participation of syntaxin-6 [58] and the
cavin-family of proteins [78–80] in this process has been demon-
strated. In certain epithelial cells, including hepatocytes, which
express abundant amounts of NPC1 [81] and AnxA6 [82–84], their
interaction may contribute to the regulation of the amount of
caveolin/caveolae and cholesterol at the cell surface. As proposed by
van Duyl et al. [85], the interaction of caveolin and cholesterol may be
fundamental to the generation of caveolae. However, caveolin-1 is not
essential for the targeting of cholesterol to DRMs and therefore,
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tion of cell architecture-dependent membrane rafts [44].
In addition, the formation of highly condensed domains (mem-
brane rafts) not only requires transport from intracellular sites to the
cell surface, but also the lateral movement of lipids and proteins into
speciﬁc cholesterol-enriched clusters. This gives rise to domains that
are distinct from the surrounding membrane by their lipid structure
(liquid-ordered vs. -disordered domains). To address if the speciﬁc
targeting or the overexpression of AnxA6 altered themembrane order
of domains in vivo, we used the ﬂuorescent dyes Laurdan and di-4-
ANEPPDHQ [86,87]. Direct visualization of membrane lipid structure
of living cells using two-photon microscopy in Laurdan-stained cells
indicated that AnxA6 seems to translocate without detectable
preference for raft or non-raft domains to the plasma membrane.
However, cells with high levels of AnxA6 showed a signiﬁcant
decrease of condensed membrane domains (Vilà de Muga and Enrich,
unpublished). These ﬁndings are in agreement with our previous data
derived from the biochemical characterization of cholesterol levels in
plasmamembrane fractions [26] and provide the ﬁrst in vivo evidence
that support a model of annexins inducing changes in the membrane
architecture. Future experiments will have to clarify if these changes
can cause altered membrane microlocalization and activity of growth
factor receptors, Ca2+-channels, lipid-anchored proteins (Ras-
GTPases), or modulate the targeting site for the transient and Ca2+-
dependent recruitment of signaling proteins (p120GAP, PKC) or even
the anchoring/recruitment of the actin cytoskeleton.
3. AnxA6 and the actin-cytoskeleton
Responses to cholesterol reduction are often taken as evidence for
a role of membrane rafts in cell function. However, depletion of cell
cholesterol has rather global effects on cell and plasma membrane
architecture and function. The lateral mobility of membrane proteins
is reduced when cellular cholesterol is chronically or acutely depleted
[88–90] and this change in mobility is a consequence of the
reorganization of the cellular actin cytoskeleton as well as membrane
condensation. As described above, different annexins, including
AnxA6, have been implicated in a variety of cellular responses to
stimulus-induced elevations in intracellular Ca2+-levels or choles-
terol perturbation/deregulation. Often these responses involve
membrane-related events ranging from changes in the number of
caveolae, signal transduction, regulation of ion ﬂux across mem-
branes or membrane trafﬁcking. However, such tasks are not only
consistent with the generic ability of annexins to bind to membranes
in a Ca2+-regulated manner, but also with the increasing number of
reports that demonstrate interaction of annexins with components of
the actin-cytoskeleton. From these studies it can be assumed that
similar to the transient nature of annexins interacting with
membranes, annexin–actin interactions are also highly dynamic
and occurring in close proximity to cellular membranes. It is probably
the concerted action of these protein–protein interactions, together
with the ability to bind membranes that enable annexins to
participate in cellular events that range from receptor-mediated
endocytosis to cell migration.
The interaction of AnxA2 with the actin-cytoskeleton has been
well documented (see [91] and references therein). AnxA2 is a
phosphatidylinositol (4,5)-biphosphate (PI(4,5)P2) binding protein
[92] that is recruited to actin assembly sites in cellular membranes
[93]. These observations add AnxA2 to the list of well-documented
changes in the localization and activity of actin-binding proteins that
modify the actin cytoskeleton [94]. Most interestingly, cholesterol
depletion disrupts the organization of PI(4,5)P2 in the plasma
membrane [95], but simultaneously increases the stability of the
cortical cytoskeleton. This indicates that major reorganizations of the
cytoskeleton depend on the loss or redistribution of plasma
membrane PI(4,5)P2 and consistent with this data, agents thatsequester plasma membrane PI(4,5)P2 mimic the effects of choles-
terol depletion on actin organization and on lateral mobility [96].
Altogether this might point at AnxA2, and possibly other annexins,
like AnxA8 [97], to organize and stabilize actin assembly sites at the
membrane or other cellular sites, such as endosomes. It has yet to be
determined if the association of AnxA6 with the actin cytoskeleton
also involves PI(4,5)P2 binding properties.
AnxA6 has been reported to bind actin ﬁlaments in a Ca2+-
dependent manner [98,99]. This binding could be responsible for the
co-localization of AnxA6 and F-actin at membrane rufﬂes [99,100] and
circular-dorsal rufﬂes (CDRs) (Reverter and Enrich, unpublished).
Some studies suggest that increased amounts of AnxA6 directly
correlate with the stabilization of cortical cytoskeleton. Along these
lines, we recently demonstrated that constitutive membrane locali-
zation of AnxA6 caused a rearrangement of F-actin at the plasma
membrane, indicative of a stabilized cortical cytoskeleton [101].
Further suggesting a general remodeling of the actin-cytoskeleton, we
observed a reduced number of stress ﬁbers in several AnxA6
overexpressing cell lines as well as U18666A-treated NRK cells,
which express substantial amounts of AnxA6 (Reverter and Enrich,
unpublished). Interestingly, studies with membrane-anchored
AnxA6, but not AnxA1 or AnxA2, revealed a role for AnxA6, via the
actin cytoskeleton, in the regulation of store-operated Ca2+-entry
(SOCE) [101–104]. Agents acting on cortical actin are well known to
interfere with the activation of SOCE: stabilization of the cortical
cytoskeleton with jasplakinolide reduces SOCE in most cells [103],
possibly by interfering with stromal interaction molecule 1 (STIM1)
function [105], whereas disruption of cytoskeleton with latrunculin A
or cytochalasin D activates Ca2+-entry [106]. Consistent with these
ﬁndings, latrunculin A abolished the inhibitory effect of membrane-
anchored AnxA6 on SOCE, further implicating that AnxA6 is a key
player linking the actin cytoskeleton with SOCE. Hence AnxA6
interaction with the plasma membrane, followed by the stabilization
of cortical actin might contribute to the attenuation of Ca2+-entry
[101].
Besides interacting with F-actin, AnxA6 was identiﬁed as a binding
partner of spectrin, and in vitro experiments suggested it could
inﬂuence the F-actin bundling activity of this protein in a Ca2+- and
PS-dependent manner [107]. Although these ﬁndings require further
investigation, it adds to suggest a possible role for AnxA6 regulating
the actin microﬁlament architecture. This is supported by the ﬁndings
of Kamal et al., which implicated that AnxA6, upon Ca2+-mobilization,
is involved in the remodeling of the spectrin cytoskeleton during
endocytosis to facilitate the release of clathrin-coated vesicles from
the plasma membrane. The binding of AnxA6 to spectrin is a
prerequisite for the recruitment of calpain I, which in turn, may
cleave the spectrin–actin cytoskeleton allowing entry of endocytic
vesicles [108]. The fact that other studies also identiﬁed calpain I in
clathrin-coated vesicles [109], together with data supporting AnxA6
binding spectrin [107] and this being required to stimulate vesicle
budding in vitro [110], suggests that AnxA6-mediated reorganization
of the spectrin cytoskeleton might indeed be necessary to allow
budding at the plasma membrane.
A potential role for AnxA6 regulating receptor-mediated endocy-
tosis via spectrin was originally proposed for the internalization of
LDL [108]. The involvement of AnxA6 in the endocytosis and
trafﬁcking of LDL was soon thereafter veriﬁed in independent studies
from our laboratories [14,111]. Interestingly, AnxA6 and spectrin-
dependent trafﬁcking events might also occur in other compartments,
as spectrin is present in membranes of the Golgi apparatus [112], in a
variety of poorly characterized intracellular vesicles [113,114] and in
macropinosomes of NIH3T3 cells [115]. Indeed, we demonstrated that
the mechanism proposed by Kamal et al. [108] for AnxA6 at the
plasma membrane seems to be operational in the late endocytic
compartment of NRK cells, to allow exit of LDL to lysosomes for
degradation [84,111].
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presence or absence of AnxA6 are likely to impact on the signaling
capacity of cells (see below). For example, several studies suggest that
activated receptor tyrosine kinase (exempliﬁed by the epidermal
growth factor receptor, EGFR; see Fig. 4) dimerization or even
oligomerization, which is accompanied by the formation of signal
protein-complexes, leads to a temporary immobilization of signal
transduction components. This is likely due to the concomitant
anchorage of these protein (and lipid) complexes with membrane-
associated actin ﬁlaments on the inner membrane leaﬂet, also
referred to as “membrane-fences” [116,117]. Thus, AnxA6-induced
changes/alterations of cholesterol distribution or spatio-temporal
actin dynamics will inﬂuence membrane functioning and signal
transduction. Based on the various observations described here, oneFig. 4. Role of AnxA6 in PKCα and Ras/MAPK signaling pathways. (A) In cells with low An
followed by EGFR internalization, lysosomal targeting and signal termination (1–4). (B) AnxA
(2). High AnxA6 levels and EGF increase Ca2+-inducible PKCαmembrane targeting to phos
reduces EGFR internalization. PKCα and AnxA6 remain associated with EGFR in early endo
membrane for another round of signaling (4–5) [9,70]. (C) (1–2) In the cytosol of resting ce
EGFR and subsequent Ca2+ stimulation, high levels of AnxA6 promote the membrane target
terminates EGFR-induced activation of HRas and the Raf-1/MAPK (Mek, Erk) pathway at the
is internalized and dissociates from H-Ras into the cytosol. Finally HRas recycles to the pl
endosomes (see B) or to late endosomes/multivesicular bodies (MVB) [9,70].can envisage that AnxA6 might be involved in the interaction of
specialized membrane rafts domains with actin-based membrane
cytoskeleton [118].
4. AnxA6 and signal transduction: cross-talk with PKCα and HRas
In the previous sections we have outlined the ability of AnxA6 to
regulate cholesterol distribution, to interact with membranes and the
actin cytoskeleton, and to modulate Ca2+ entry in cells. These
features, together with the ability of AnxA6 to interact and recruit
signaling proteins for the formation of membrane-associated multi-
protein complexes, are likely to create unique and compartment-
speciﬁc signaling platforms in membrane microdomains. In the
following we would like to highlight the scaffolding role of AnxA6xA6 levels, binding of EGF to EGFR induces EGFR tyrosine phosphorylation (P). This is
6-mediated targeting of PKCα to inhibit EGFR. AnxA6 interacts with PKCα in the cytosol
phorylate EGFR at Thr654 (P-Thr654). This inhibits EGFR tyrosine phosphorylation and
somes (EE) (3). AnxA6 and PKCα dissociate from EGFR, which recycles to the plasma
lls, AnxA6 interacts with p120GAP (GTPase activating protein). Upon binding of EGF to
ing of p120GAP to the cell surface and possibly early/sorting endosomes EE/SE. (3) This
plasmamembrane (and possibly in endosomes). (4) Then the AnxA6/p120GAP complex
asma membrane for another round of signaling and (5) EGFR is targeted to recycling
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transduction pathways and provide excellent examples how annexins
link membrane microdomains with Ca2+ signaling and signal output
in various cellular processes.
4.1. AnxA6 is a scaffolding protein regulating PKCα effector pathways
AnxA6 interacts with several signaling proteins and we refer the
reader to previous reviews from our laboratories for more compre-
hensive surveys with a more complete list of kinases and other
proteins interacting with AnxA6 [9,70,71]. In the following we would
like to brieﬂy summarize our current understanding of AnxA6
regulating a member of the protein kinase C (PKC) family, PKCα.
Protein kinase C (PKC) is a family of serine/threonine kinases with
at least 12 protein isoforms expressed in mammals. PKC isoforms are
highly homologous in their catalytic domain, and their speciﬁc
regulatory domains determine the response to activators. When
inactive, PKC is auto-inhibited by a pseudosubstrate sequence that is
present in the regulatory domain. The classical PKC isoforms (α, βI, βII
and γ) are activated by the second messengers calcium and
diacylglycerol (DAG), whereas novel PKC isoforms (ε, δ, θ and η)
respond only to DAG. Atypical PKCs (ζ, λ/ι) are not responsive to
either of the secondmessengers. This activation typically occurs at the
plasma membrane, but it has become evident that activation of PKC
also takes place in other cellular compartments, such as endosomes,
Golgi and mitochondria [119,120].
It is now well-established that the complex and spatio-temporal
targeting of individual PKC isozymes to unique subcellular localiza-
tions to promote and control phosphorylation of PKC isozyme
substrates is facilitated by PKC-isozyme-speciﬁc scaffold proteins, in
particular Receptors for activated C kinase (RACKs) and AKAP79/150
[119,121–123]. Both RACK and AKAP79/150 reside on the inner leaﬂet
of membranes to selectively bind a particular PKC isozyme only in the
active conformation. In addition, annexins seem to provide a new
class of PKC scaffold proteins and shuttle PKC isozymes from the
cytosol to the membrane in a Ca2+-dependent manner [9,34,121].
Indeed, a role for annexins in PKC activation may be a common theme
in PKC signaling. AnxA5 has been proposed to shuttle PKCδ from the
cytosol to the membrane [124], while AnxA1 and AnxA2 interact with
PKCβ and PKCε, respectively [125,126]. Schmitz-Peiffer et al. [127]
provided initial biochemical evidence for PKCα–Anx6 interaction.
This was followed by in vitro experiments showing that AnxA6 is
phosphorylated by PKC, possibly within a PKC motif in the AnxA6
linker region at Thr356 [128,129]. The inability of the AnxA61–175
deletion mutant (lacking the AnxA6 linker) to promote PKCα
membrane recruitment [34], together with the fact that the AnxA6
linker binds to C2 domains of other proteins (e.g. p120GAP, see below
[130]), suggests that the AnxA6–PKCα interaction occurs via the
AnxA6 linker and PKCα C2 domain. Unpublished data from our
laboratories now demonstrates that membrane-anchored AnxA6 can
act as a docking site for PKCα even in the absence of Ca2+ (Koese,
Grewal and Enrich, unpublished). Thus the C2 domain in PKCαmight
not only be critical for membrane association through Ca2+-sensing
and PS binding, but also via unique protein–protein interactions.
Several observations have shown that PKCα could regulate
receptor tyrosine kinases, including EGFR and downstream effector
pathways, such as the Ras/MAPK signaling cascade at different levels.
Most interestingly, PKCα phosphorylates EGFR at threonine 654
(Thr654), which inhibits EGFR tyrosine kinase activity and the
associated mitogenic response [131–135]. Furthermore, PKC-mediat-
ed Thr654 phosphorylation of EGFR also reduces ligand-dependent
EGFR internalization and lysosomal degradation, as inactive EGFR is
diverted to recycling endosomes for transport back to the cell surface
[136,137]. More recent studies implicate that caveolin-1 (among
others) is required for PKCα-mediated EGFR inhibition [138].
Although EGFR seems to distribute randomly on the cell surface[139,140], this might point at AnxA6 possibly being involved in
selective and spatial–temporal inactivation of EGFR in cholesterol-rich
membrane domains. The fact that earlier studies suggest a preference
of PKCα to target caveolae at the cell surface [141] and that both
AnxA6 and PKCα translocate to membrane rafts [42,43,142], indicate
that both proteins may translocate to membrane rafts together in a
Ca2+-dependent manner to downregulate a subpopulation of active
EGFR. In support of this, preliminary results from our laboratories
indicate that increased amounts of AnxA6 could establish a microen-
vironment promoting PKCα and EGFR interaction, followed by EGFR
inactivation. In fact, high levels of AnxA6 increase PKCα membrane
targeting to phosphorylate Thr654-EGFR. This mechanism is opera-
tional in A431 cells, but also in various other cancer cell lines with de-
regulated EGFR activity and correlates with an inhibition of EGFR
tyrosine phosphorylation and reduced EGFR internalization and
degradation (Koese, Grewal and Enrich, unpublished). It has yet to
be determined how two potentially opposing activities of AnxA6: (1)
reducing the amount of caveolin/caveolae at the cell surface (see
Section 2) and (2) inhibiting EGFR in membrane rafts/caveolae
are coordinated. It is well believed that the differential involvement of
Ca2+, the membrane microenvironment and the actin cytoskeleton
contribute to regulate magnitude and spatio-temporal pattern of
EGFR activation. Expression levels of AnxA6, PKCα, EGFR and caveolin
in different cell types might provide an opportunity for the ﬁne-
tuning of these activities to modulate EGFR signaling in cancer.
Besides AnxA6 being instrumental for PKCα in EGFR signal
termination, we have demonstrated that HDL-induced activation
Ras/MAPK signaling via scavenger receptor BI (SR-BI), possibly in
caveolae, becomes PKCα-dependent in CHO cells ectopically expres-
sing AnxA6 [34]. Recent ﬁndings suggest that these signaling cascades
are involved in the regulation of SR-BI and ATP binding cassette (ABC)
transporter A1 protein stability, but also cPLA2 activation (Wood,
Enrich and Grewal, unpublished), making these ﬁndings potentially
relevant for molecular events in peripheral cells, such as macro-
phages, but also hepatocytes, during the development of atheroscle-
rosis and inﬂammation. In these studies we also demonstrated that
HDL-induced activation of Ras activates the phosphatidylinositol-3-
kinase (PI3K)/Akt pathway [34]. Given that large amount of AnxA6 are
found in endothelial cells, these results might point at a regulatory
role for AnxA6 in the PI3K/Akt- and SR-BI-dependent activation of
eNOS in membrane rafts of endothelial cells.
The underlying mechanisms how AnxA6 increases the involve-
ment of PKCα in the HDL-induced activation of the Ras/MAPK and
PI3K/Akt pathway is yet unclear. Earlier studies implicated PKC in Ras
activation and inhibition of p120GAP [143,144]. Consistent with HDL
signal transduction via SR-BI predominantly occurring in membrane
rafts, we showed that HRas, one of the Ras isoforms found in
membrane rafts and sensitive to cholesterol depletion is inhibited by
AnxA6 [34]. These ﬁndings correlate with reduced MAPK and Akt
activation. Although PKC can act on Ras effectors at any level,
including Raf-1, MAPK, PI3K and Akt, HDL-induced elevation of Ca2+
stimulated an event further upstream, the AnxA6-mediated assembly
of p120GAP with HRas (see Section 4.2). As AnxA6 can directly
interact with HRas, this could suggest a direct involvement of PKC in
Ras activation that requires the presence of AnxA6 [34].4.2. AnxA6 as a scaffolding protein for the Ras/MAPK pathway
In this ﬁnal section we will summarize the data that makes AnxA6
central to the downregulation of the Ras/MAPK pathway, one of the
most important signaling cascades that controls cell proliferation and
differentiation. More detailed reviews on the inhibitory action of
AnxA6 on Ras/MAPK activity can be found elsewhere [9,71]. Here we
would like to focus on recently published data that emphasizes the
relevance of these interactions in certain cancer cells and identiﬁes
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breast cancer cells with de-regulated EGFR activity [38].
Ras-GTPases act as binary switches that cycle between an inactive
(Ras-GDP) and an active conformation (Ras-GTP). Upon binding of
growth factors, hormones and nutrients to cell surface receptors, Ras
becomes activated and is able to recruit and activate Raf-1, Mek1/2
and Erk1/2 effector proteins, commonly known as the Raf/MAPK
pathway, which ultimately controls proliferation and differentiation.
The ratio of bound GTP to GDP determines the activity of Ras and is
regulated by nucleotide exchange factors (GEFs) and GTPase
activating proteins (GAPs). However, while the molecular mechan-
isms and signaling events in the canonical Ras/MAPK pathway have
been relatively well understood, fundamental insights are still needed
for a better understanding how Ras activation can create differential,
cell and tissue-speciﬁc signal output, possibly in a spatio-temporal
manner, that might contribute to oncogenic events in Ras-related
cancers.
Evidence from animal and cell culture models ﬁrst revealed that
the three highly conserved Ras isoforms, H-, K- and NRas have
functional differences [145,146]. The basis of signal speciﬁcity is
partially explained through the compartmentalization and lateral
segregation of H-, K- and NRas in different microdomains at the
plasma membrane, as well as Ras isoform-speciﬁc signaling from
different endomembranes [145,147,148]. Together with differential
recruitment of Ras effectors, it is generally believed that the local
balance of GEFs and GAPs contributes to Ras isoform speciﬁc
activation status and its downstream target pathways [149–151].
However, both GEFs and GAPs involve large and divergent protein
families, and current research is still in early stages to clarify which
GEF/GAP family member is speciﬁcally recruited to Ras isoforms to
mediate a certain biological response. As exempliﬁed by AnxA6,
studies from our laboratories and others strongly suggest that the
relative amount of cell-speciﬁc scaffold and adaptor proteins
determines the targeting, assembly and stabilization of Ras-contain-
ing signaling protein complexes directly via protein–protein interac-
tion or indirectly via membrane microdomain formation and
stabilization [71,147,148,152–156].
GAPs are the most important negative regulators of Ras and
require translocation to the plasma membrane, followed by Ras/GAP
assembly and stimulation of Ras GTPase activity. This is a critical
step in 20% of human cancers, as Ras mutations in codon 12 (G12V)
and 61 (Q61L) cannot be switched off and remain constitutively
active [149,151,157]. While oncogenic Ras is resistant to GAP
activity, overexpression of EGFR, which is common in breast, head
and neck, and several other cancers, leads to aberrant activation of
wild-type (hyperactive) Ras [71,158,159]. This phenomenon is not
fully understood, as ubiquitous expression of several GAP family
members at signiﬁcantly high levels should be sufﬁcient to down-
regulate hyperactive Ras activity. Thus, additional factors seem to
determine the contribution of GAPs in EGFR-dependent Ras signal
termination.
Given that we and others have demonstrated that AnxA6 binds to
the ubiquitously expressed p120GAP [38,130,160], which is the only
GAP known to bind EGFR [161–163], we hypothesized that AnxA6
expression levels determine the involvement of p120GAP in EGFR-
induced Ras inactivation. Several lines of evidence support this model.
The interaction of AnxA6 with p120GAP has been reviewed in detail
[71]. In brief, cytosolic pools of AnxA6 constitutively bind to p120GAP
via the linker region of AnxA6 and the C2 domain of p120GAP
[130,160]. As the C2 domain of p120GAP does not contain the
aspartate residues known to coordinate Ca2+-dependent membrane
binding, it was proposed and later veriﬁed that AnxA6 is the Ca2+
sensor to facilitate p120GAP membrane targeting [35,164,165]. Upon
cell activation, this would still allowAnxA6 to bindmembranes via the
annexin-core domains and p120GAP to bind active and membrane-
bound HRas-GTP, followed by Ras inactivation [35]. It is evident thatthe multiple features that determine AnxA6 membrane and actin
binding, together with the p120GAP C2 domain, but also the SH2, SH3
and PH domain within p120GAP, create a unique combination of
targeting signals that may direct protein–phospholipid or protein–
protein interactions in speciﬁc locations at the plasmamembrane, but
also in endosomes.
Recently we addressed the relevance of our ﬁndings in breast
cancer [38]. Indeed, AnxA6 is downregulated in a number of EGFR
overexpressing and estrogen receptor (ER) negative breast cancer
cells (BCCs). In these cells, AnxA6 overexpression promotes Ca2+ and
EGF-inducible membrane targeting of p120GAP. Further pointing at
AnxA6 expression levels creating signal speciﬁcity, overexpression of
p120GAP, but not CAPRI, another Ca2+-dependent GAP protein, or a
p120GAP mutant lacking the AnxA6 binding domain, inhibits Ras/
MAPK activity in ER-negative MDA-MB-436 cells. Vice versa, in these
cells knockdown of AnxA6 increases Ras activity and cell proliferation
in anchorage-independent growth assays. Mechanistically, we iden-
tiﬁed by FRET microscopy that AnxA6 is in close proximity of active
(G12V), but not inactive (S17N) HRas. Although the protein domains
facilitating AnxA6–HRas interaction have yet to be determined, these
ﬁndings strongly suggest that AnxA6 is part of and stabilizes an HRas-
GTP/p120GAP complex. The fact that AnxA6 has also been identiﬁed
in EGFR containing protein complexes, is tyrosine phosphorylated at
Tyr30 in lung cancer [166,167] (Koese, Grewal and Enrich, unpub-
lished), and inhibits EGFR activation (see Section 4.1), together with
previous reports from our laboratory that AnxA6 interacts with Raf-1
[32], implicate that the scaffolding function of AnxA6 goes beyond
HRas/p120GAP assembly, but might determine EGFR signal complex
formation in certain cell types. In particular in EGFR overexpressing
cells, AnxA6 could be a tumor suppressor to reduce the transforming
potential of EGFR and hyperactive Ras. Previous studies showing
reduced growth of EGFR overexpressing A431 cells ectopically
expressing AnxA6 in mouse xenograft models strongly support this
hypothesis [36].
Hence, low AnxA6 levels in EGFR overexpressing and ER-negative
BCCs indicate downregulation of AnxA6 due to EGFR/Ras-induced
transforming events, thereby depleting the cell of a scaffold required
for EGFR and Ras inactivation. But what causes AnxA6 downregula-
tion? An attractive hypothesis might be epigenetic silencing observed
for several annexins in cancer tissues [168,169]. Similarly, we
determined that the AnxA6 promoter was heavily methylated only
in AnxA6-deﬁcient A431 [170] and BCCs, both overexpressing EGFR
(approx. 1–5×106 EGFR/cell) [38]. In addition, several studies showed
a signiﬁcant loss of 5q31–q35, which carries the AnxA6 locus, in ER-
negative tumors associated with gene ampliﬁcations of another
member of the EGFR family with strong oncogenic potential, ErbB2.
The involvement of AnxA6 might even extend to other cancers. For
instance the 5q-syndrome, a large deletion on chromosome 5q that is
associated with the myelodysplastic syndrome and risk of transfor-
mation to acute myelogenous leukemia (AML), was recently
narrowed down to 1.5 Mbp within 5q31–32. This region harbors
around 40 genes, some of those, including AnxA6, with tumor
suppressor properties [171]. Thus, AnxA6 might display tumor
suppressor activity only in the context of certain genetic lesions or
susceptible cell types.
Finally, it should be noted that the two mRNA splice variants of
AnxA6 (AnxA6-1 and AnxA6-2) complicate the understanding of
AnxA6 functions [172,173]. AnxA6-1 (the larger isoform) is predom-
inantly expressed in normal cells and tissues, and AnxA6-2 appears
more abundant in some transformed cell lines [174]. Up to date, only
the inhibitory effect of the AnxA6-1 mRNA isoform, but not AnxA6-2,
on EGF-dependent Ca2+ inﬂux in A431 cells has been described [175].
Although AnxA6-2 has a higher afﬁnity for Ca2+, lower hydrophobic-
ity and lower negative surface charge [176], the relationship between
expression levels of AnxA6 splice variants and cellular transformation
is yet unknown.
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activation leads to an increase of intracellular Ca2+ levels, which
promotes the AnxA6-induced targeting of p120GAP and PKCα to
EGFR- and HRas-containing protein complexes at the plasma
membrane. This is followed by (a) increased HRas/p120GAP assembly
and Ras inactivation and (b) PKCα-mediated Thr654 phosphorylation
to inhibit EGFR tyrosine phosphorylation. This reduces EGFR inter-
nalization and during this process, AnxA6 remains associated with
EGFR, HRas, p120GAP and PKCα to ensure EGFR/Ras signal termina-
tion in early endosomes. Finally, AnxA6, p120GAP and PKCα are
released into the cytosol, whereas EGFR and HRas are targeted to the
plasma membrane via recycling endosomes for another round of
signaling [71].
5. Concluding remarks
In summary, the ability of AnxA6 to target signaling proteins to
membranes in a Ca2+-dependent manner, together with its capacity
to modulate cholesterol homeostasis, cPLA2 activity and cell
architecture through actin remodeling, probably allows AnxA6 to
contribute to the formation of compartment-speciﬁc membrane
domains and signaling platforms. Dissecting the ﬁne-tuning of
AnxA6 expression and localization, together with the mapping of
interaction domains, will ultimately provide a better understanding
of the spatio-temporal links between Ca2+ signaling and cholesterol
transport in membrane transport, actin remodeling and signaling in
complex human diseases.
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